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NMHSCT may potentially achieve a graft-vs-malignancy effect
mediated by donor-derived T cells. From 1/10/00 through 9/9/03
we treated 50 pts with NMHSCT using a preparative regimen of
ﬂudarabine 30 mg/m2/d IV on days -5, -4, -3, and total body
irradiation 200 cGy on day -1. Diagnoses included 12 NHL, 9
AML, 7 CML, 6 myeloma, 4 MDS, 4 MFB, 4 renal cell carcinoma,
2 CLL and 2 Hodgkin’s lymphoma. The median CD34 and
CD3 cell doses infused were 6.64 x 106/kg and 3.74 x 108/kg,
respectively. 14 pts had matched unrelated donors (MUD). T cell
(CD3) chimerism was monitored by short tandem repeat analy-
sis. Mixed chimerism (MC) consisted of1% to99% host DNA.
Thirty (60%) pts achieved T cell complete donor chimerism
(CDC) at a median of 63 days (range 14-400) with 7 (50%) MUD
pts and 23 (64%) related donor pts achieving CDC. 32 (64%) pts
developed acute GVHD at a median of 34 days (range 8-97) with
12 grade 1, 7 grade 2, 8 grade 3 and 5 grade 4. At the time acute
GVHD developed the median % of donor T cell DNA was 90%
(range 37-100) and only 11 (34%) of these pts had achieved CDC.
19 (38%) pts developed chronic GVHD at a median of 196 days
(range 104-531) and at the time of its detection 15 (79%) pts had
achieved CDC. GVHD developed in 9 (64%) MUD pts and in 29
(81%) related donor pts. There were 19 (38%) pts with either
disease relapse/progression at a median of 117 days (range 17-639)
which occurred in 8 pts with CDC, in 8 pts with MC and in 3 pts
with graft failure. 13 (26%) pts achieved CR with 9 having stable
CDC, 3 with stable MC without ever achieving CDC and 1 pt had
a graft failure. 6 pts achieved a PR with 3 having stable CDC, 2
with MC without ever achieving CDC, and 1 pt not evaluable for
T cell chimerism. At 10 months median follow-up (range 0.7-42
mos) 25 (50%) pts have died. 11 (44%) of these pts had stable
CDC, 7 never achieved CDC with 3 of them proceeding to a full
ablative HSCT, 5 achieved CDC which reverted to MC and then
back to stable CDC, 1 achieved CDC but due to conversion to MC
underwent a full ablative HSCT, and 1 pt was not evaluable for T
cell chimerism. We conclude that post-transplant monitoring of T
cell (CD3) chimerism is important to allow for immune manip-
ulation to maintain a state of donor-host tolerance in order to
prevent graft rejection. Acute GVHD commonly occurs after
NMHSCT without achieving CDC, whereas pts who develop
chronic GVHD as well as those who attain disease responses are
more likely to have CDC.
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ONE HUNDRED CHILDREN UNDERGOING ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION WITH CYCLOPSPORIN (NEORAL) BY MOUTH
Mazzolari, E.1, Porta, F.1, Forino, C.1, Gandellini, F.1, Maffeis, B.1,
Caldiani, C.1, Rodriguez, C.1, Lanfranchi, A.2 1. Dept of Pediatrics,
Brescia, Italy; 2. Laboratorio Trapianti, Brescia, Italy.
Bone marrow transplantation is performed as an elective therapy
in children affected by onco-haeamtological and genetic diseases.
Since 1996 we have grafted 100 children affected by onco-haeam-
tological diseases from haploidentical (14), matched unrelated (60),
identical (26) by using cyclosporin (Neoral) by mouth. In all cases
cyclosporin have been administred all through the transplant, with-
out using the drug IV. All patients receive preaparative chemio-
therapy regimens before transplant, among our patients , 25 af-
fected by acute leukemias received total body irradiation. Mean age
at transplant was 3,5 years (age range 1 month-12 years). In all
cases cyclosporin levels were within the normal range. Incidence of
acute GVHD grade III/IV was 12%, chronic GVHD 4 %.Trans-
plant related mortality was 18%. None of the children presented
side effects related by cyclosporin administration. Our experience
demonstraed that in pediatrics there is no need of intravenous
administrationof cyclopsorin.
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HAPLOIDENTICAL TRANSPLANTS FROM POSITIVELY SELECTED BONE
MARROW HAEMATOPOIETIC STEM CELLS: REPORT OF 20 CASES
Lanfranchi, A.1, Verardi, R.1, Baggio, E.1, Mazzolari, E.2, Porta, F.2
1. Laboratorio Trapianti, Brescia, Italy; 2. Clinica Pediatrica, Brescia,
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Genetic diseases affecting haematopoietic and immune systems
can be cured by bone marrow transplantation (BMT). Haploiden-
tical BMT is the treatment of choice in many cases since is uneven
to have an healthy matched family donor in family trees affecte by
a genetic disease. Moreover the search of matched unrelated donor
can take long (3-6 months)and succeed in 70% of the cases. Since
1983 haploidentical traplants have been performed by T cell de-
pletion. In our experience we have performed 40 haploidentical
transplants by Campath 1M bone marrow T cell depletion in
children affected by genetic diseases from 1991 to 1996. The
overall engraftment rate was 60%, but the event free survival did
not exceeded 40%. Camtpath 1M recognized CD52 positive cells,
that meant T cells, B cells, monocytes, plasmacells and approxi-
mately 50% of CD34 cells. Reasons of relative unsuccess were
maybe related to a profound depltion of accesory cells within the
bone marrow suspension. Since 1996 we utilized Clinimacs clinical
device to perform positive selection of haetopoietic stem cells.
Since we are treating genetic diseases the children affected have a
mean age of 2,5 years, therefore the weight at transplant do not
exceed 10 kg. We have performed 20 haploidentical transplants
positively selecting haematopoietic stem cells from bone marrow.
The children were affected by severe combined immunodeﬁcine-
cies(SCID) and other primary immunodeﬁciencies. The mean
yield of stem cells was 75% of the initial stem cell count, while the
purity of the stem cells was 91. 8%. Engraftment rate was 90%
with a mean time for complete immune reconstitution that did not
exceed 3 months.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF
12 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN
BRAZIL
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Lorenzatto, C., Ruiz, J., Neves, H., de Medeiros, C.R., Zanis-Neto, J.,
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Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a
clonal disorder caused by acquired mutations of the PIG-A gene.
Stem Cell Transplantation (SCT) with an HLA identical sibling is
potentially curative for young patients with severe pancytopenia,
massive hemolysis or serious thrombotic complications. Material
and Methods: We performed a retrospective analysis of 12 pts who
underwent a non T cell depleted SCT from HLA identical donors
at our institution between 03/1988 and 04/2003. Indication for
SCT: severe pancytopenia: 9 pts, thrombosis: 2 pts and hemolysis:
1 pt. The conditioning regimen consisted of BU12mg/kg  CY
120mg/kg: 8 pts (1 pt received BU16mg/kg), BU 8mg/kg  Flu-
darabine 125mg/m2: 1 pt and CY 200mg/kg: 1 pt. Bone marrow
was the stem cell source for 11 pts while 1 pt received peripheral
blood. All but one pt received methotrexate cyclosporine as graft
versus host disease (GVHD) prophylaxis. All pts received prophy-
lactic antibiotics with ﬂuconazol, sulfamethoxazole-trimethoprim
and acyclovir according to common practice. Results: Pts charac-
teristics: Median age at transplantation: 27, 5 years (range: 14-42
yr); Gender: 4F/8M. Time from diagnosis to SCT was a median of
16 months (range: 2-133m). A median of 22, 5 UI of blood
transfusions were given before transplant (range: 8-200 UI). Total
nucleated cell infused: 1, 72-12, 3 x 108/kg (Median: 2, 74). All pts
surviving more than 28 days engrafted at a median of 18 days
(range: 15-25 days). Mucosytis grade III-IV occurred in 6 pts. Two
patients developed grade III-IV acute GVHD. Two pts had exten-
sive chronic GVHD : One progressed after A-GVHD and the
other one had a de novo extensive C-GVHD. No pt developed
veno-occlusive disease. Eight pts are alive and well with a median
follow up of 3038 days (range: 176-5662). Four pts (Median age:
36,5yr) died on day 10, 11, 71 and 330 after SCT. Causes
of death included infection (2) and GVHD (2).Estimated 9 year
overall survival is 66% (95% CI). Conclusion: We conclude that
pts with PNH and life threatening complications can achieve long
term survival after this conditioning regimen. These pts can be
offered an allogeneic STC if they have an HLA identical sibling
and develop severe pancytopenia, hemolysis or recurrent throm-
bosis.
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